Phase 1 Brain Cancer Trial, Recruiting NCT03830151 Sponsor: M.D. Anderson Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 1 Brain Cancer Trial, Recruiting

NCT03830151
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to provide written agreement to take part in the study, including healthy volunteers.
  • Healthy volunteers who do not have any reason they cannot safely have an MRI scan.
  • People who are already enrolled in a related study called the Stereotactic RadPath trial (study #2011-0370).
  • People who are 18 years of age or older and are willing to attend all required visits and assessments.
  • People who have a brain lesion that is either suspected to be, or has already been confirmed by biopsy to be, a primary brain tumour, and who are being considered for surgical removal of that tumour.
  • People who are able to understand the study information and provide their own consent to participate.
  • People who are willing to have an MRI scan (including specialised imaging of blood flow, water movement, and brain chemistry) within 14 days before the planned procedure, and ideally within 3 days.
  • People whose kidneys are functioning well enough (a kidney function score above 60); people with moderate kidney function (score between 30 and 60) may still be considered, with a different contrast agent used if a contrast scan is medically necessary (confirm with trial site).
  • People who are willing to provide separate signed consent for a specific type of scan called C13-Pyruvate MR Spectroscopy.

Who may not be able to join:

  • People whose brain anatomy makes it unsafe to perform a stereotactic biopsy (a type of guided needle procedure).
  • People who have certain implanted devices or medical conditions that make MRI unsafe, including but not limited to: pacemakers, automatic defibrillators, insulin pumps, nerve stimulators, cochlear implants, carotid sinus pacemakers, ferromagnetic clips in the brain or body, metallic fragments in the eye, non-MRI-safe wires, suspected faulty prosthetic heart valves, or certain types of ear implants.
  • People who are pregnant, or who experience claustrophobia that does not improve with oral medication.
  • People who have previously received treatment for a primary brain tumour, such as surgery (other than biopsy), radiation therapy, or chemotherapy. A previous biopsy alone does not disqualify someone. A past history of a non-brain cancer that is now in remission for more than 6 months, with no brain involvement, also does not disqualify someone.
  • People who have a history of irregular heart rhythms (cardiac arrhythmia).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dawid Schellingerhout, M.D. Anderson Cancer Center

Phone: 713-794-5673

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
16 May 2019
Est. completion
31 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Successful collection of hyperpolarized pyruvate magnetic resonance (MR) (HMR) imaging data

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov